Intervention Review

You have full text access to this OnlineOpen article

Mass drug administration for malaria

  1. Eugenie Poirot1,2,
  2. Jacek Skarbinski1,
  3. David Sinclair3,
  4. S Patrick Kachur1,
  5. Laurence Slutsker1,
  6. Jimee Hwang1,2,*

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 9 DEC 2013

Assessed as up-to-date: 28 FEB 2013

DOI: 10.1002/14651858.CD008846.pub2


How to Cite

Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD008846. DOI: 10.1002/14651858.CD008846.pub2.

Author Information

  1. 1

    Centers for Disease Control and Prevention, Malaria Branch, Atlanta, GA, USA

  2. 2

    University of California San Francisco, Global Health Group, San Francisco, USA

  3. 3

    Liverpool School of Tropical Medicine, Department of Clinical Sciences, Liverpool, UK

*Jimee Hwang, Malaria Branch, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, Mailstop F-22, Atlanta, GA, 30341, USA. gdq1@cdc.gov.

Publication History

  1. Publication Status: New
  2. Published Online: 9 DEC 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 MDA versus no MDA in areas of low endemicity (Stratified by study design), Outcome 1 Parasitaemia Prevalence: Cluster-randomized trials.
[Analysis 1.2]
Analysis 1.2. Comparison 1 MDA versus no MDA in areas of low endemicity (Stratified by study design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 1.3]
Analysis 1.3. Comparison 1 MDA versus no MDA in areas of low endemicity (Stratified by study design), Outcome 3 Gametocytaemia Prevalence: Cluster randomized trials.
[Analysis 2.1]
Analysis 2.1. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design), Outcome 1 Parasitaemia Prevalence: Non-randomized controlled studies.
[Analysis 2.2]
Analysis 2.2. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 2.3]
Analysis 2.3. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design), Outcome 3 Gametocytaemia Prevalence: Non-randomized controlled studies.
[Analysis 2.4]
Analysis 2.4. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design), Outcome 4 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 3.1]
Analysis 3.1. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 1 Parasitaemia Prevalence: Cluster-randomized trials.
[Analysis 3.2]
Analysis 3.2. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 2 Parasitaemia Prevalence: Non-randomized controlled studies.
[Analysis 3.3]
Analysis 3.3. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 3 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 3.4]
Analysis 3.4. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 4 Parasitaemia Incidence: Cluster-randomized trials.
[Analysis 3.5]
Analysis 3.5. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 5 Gametocytaemia Prevalence: Cluster-randomized trials.
[Analysis 3.6]
Analysis 3.6. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 6 Gametocytaemia Prevalence: Non-randomized controlled studies.
[Analysis 3.7]
Analysis 3.7. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 7 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 3.8]
Analysis 3.8. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 8 Anaemia Prevalence: Cluster-randomized trials.
[Analysis 3.9]
Analysis 3.9. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design), Outcome 9 Mortality: Cluster-randomized trials.
[Analysis 4.1]
Analysis 4.1. Comparison 4 MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study design), Outcome 1 Parasitaemia Prevalence: Non-randomized controlled studies.
[Analysis 4.2]
Analysis 4.2. Comparison 4 MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 4.3]
Analysis 4.3. Comparison 4 MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study design), Outcome 3 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 5.1]
Analysis 5.1. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design), Outcome 1 Parasitaemia Prevalence: Non-randomized controlled studies.
[Analysis 5.2]
Analysis 5.2. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 5.3]
Analysis 5.3. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design), Outcome 3 Gametocytaemia Prevalence: Non-randomized controlled studies.
[Analysis 5.4]
Analysis 5.4. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design), Outcome 4 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Parasitaemia Incidence studies, Outcome 1 MDA versus no MDA: Uncontrolled before-and-after studies.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Parasitaemia Incidence studies, Outcome 2 MDA + vector control versus no MDA: Uncontrolled before-and-after studies.
[Analysis 7.1]
Analysis 7.1. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline), Outcome 1 Parasitaemia Prevalence during MDA.
[Analysis 7.2]
Analysis 7.2. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline), Outcome 2 Parasitaemia Prevalence 1-3 months post MDA.
[Analysis 7.3]
Analysis 7.3. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline), Outcome 3 Parasitaemia Prevalence during MDA.
[Analysis 7.4]
Analysis 7.4. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline), Outcome 4 Parasitaemia Prevalence <1 month post MDA.
[Analysis 7.5]
Analysis 7.5. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline), Outcome 5 Parasitaemia Prevalence 1-3 months post MDA.
[Analysis 7.6]
Analysis 7.6. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline), Outcome 6 Parasitaemia Prevalence 4-6 months post MDA.
[Analysis 8.1]
Analysis 8.1. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species), Outcome 1 Parasitaemia Prevalence at baseline.
[Analysis 8.2]
Analysis 8.2. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species), Outcome 2 Parasitaemia Prevalence during MDA.
[Analysis 8.3]
Analysis 8.3. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species), Outcome 3 Parasitaemia Prevalence <1 month post MDA.
[Analysis 8.4]
Analysis 8.4. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species), Outcome 4 Parasitaemia Prevalence 1-3 months post MDA.
[Analysis 8.5]
Analysis 8.5. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species), Outcome 5 Parasitaemia Prevalence 4-6 months post MDA.
[Analysis 8.6]
Analysis 8.6. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species), Outcome 6 Parasitaemia Prevalence >12 months post MDA.